← Issue №17/ week of Oct 25, 2026/IBD

Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD prospective cohort · n=234 · Oct 22, 2026 · Clin Gastro Hep · IF 16.2

Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study.

New evidenceCrohn's diseaseulcerative colitisbiologicstherapeutic drug monitoring
Clinical takeawayConsider guselkumab as a treatment option for patients with moderately-to-severely active Crohn's disease or ulcerative colitis, given its high remission rates and favorable safety profile in real-world settings, but note that 6.4% experienced adverse events, with 7 patients discontinuing treatment.
What it foundWeek 12 clinical remission was achieved in 76.8% of patients with CD (HBI<5) and 80.7% of patients with UC (SCCAI≤2), with remission maintained at 6 months in 88.4% of CD and 85.4% of UC patients.
ContextConfirms the efficacy and safety of guselkumab observed in pivotal trials, providing real-world evidence supporting its use in IBD, with a comparator of standard of care.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

… Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. … Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. … Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Shafrir A … Rubin DT · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues